Many life sciences companies want to tap into the anti-aging industry with the hope of producing the next Botox. NAYAderm, a biotechnology company, brought its pitch to the IMPACT conference in Philadelphia this week.
It licensed a biologic previously used for wound healing from a Japanese manufacturer. It also signed an agreement with the same company for access to the manufacturer’s preclinical and clinical historical data. The biologic, referred to as ND-101, is injected into the skin. It has a plumping effect, making it appear smoother and less drawn.
CEO and co-founder Alok Ghosh said the company was raising $5.2 million in a Series A round to bring it through Phase 2A clinical trials. He said in contrast to laser treatments, its approach was much less painful. Ghosh previously was vice president of franchise and business development at Johnson & Johnson’s diabetes care franchise.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
So far it has conducted trials in Japan where 340 hands have been treated with ND-101.
He noted, “The nice thing about the hands is that we can inject one and the other can serve as the control.”
At the time NAYAderm got started, a couple of anti-aging companies had some notable exits —Kythera Biopharmaceuticals had done an IPO and another, Skin Medica, was acquired by Allergan.
[Image of wrinkled old man by flickr user Dietmar Temps]
